In the effort to further understand Methicillin-resistant Staphylococcus aureus (MRSA) enteritis, a condition where MRSA abnormally proliferates in the intestinal tract post antimicrobial administration leading to enteritis, researchers from numerous departments of Kochi Medical School Hospital, Japan conducted epidemiological studies. This was driven by the need to establish precise diagnostic criteria due to current uncertainties. MRSA enteritis typically presents in cases where MRSA is detected in stool cultures.
The research team considered data from patients who tested positive for MRSA via stool cultures conducted 48 hours post hospital admission between April 1, 2012, and December 31, 2022. The selected cases did not meet the set exclusion criteria. Cases of MRSA enteritis or Group A were distinguished as those that responded positively to vancomycin hydrochloride powder treatment, had a Bristol Stool Scale of ≥ 5, and had a stool frequency of a minimum of three times per day. Contrastingly, all other patients, known as MRSA carriers or Group B, did not portray such characteristics.
The results of the study exhibited that Groups A and B consisted of 18 (25.4%) and 53 (74.6%) patients, respectively. Concurrently, white blood cell count of > 10000/μL, MRSA count of ≥ 2+ in stool cultures, and meropenem administration within 1 month of stool specimen submission were determined as risk factors of MRSA enteritis. Thus, the researchers concluded that the review of these case definitions could provide valuable insight as diagnostic criteria for MRSA enteritis, leading to enhanced methods of infection prevention in healthcare settings.